Daiichi Sankyo says it has begun producing AstraZeneca's COVID-19 vaccine in Japan

JCR Pharmaceuticals

12/03/2021 02:00

(Repeats to attach to alert)
    TOKYO, March 12 (Reuters) - Daiichi Sankyo Co  4568.T  said
on Friday it had begun the production of AstraZeneca Plc's
 AZN.L  COVID-19 vaccine in Japan.
    The drugmaker said in a release it will prepare the vaccine
in Japan, including vial filling and packaging, using the bulk
solution provided by AstraZeneca. 
    The Japanese government has already arranged to buy 120
million doses of AstraZeneca's vaccine, enough for 60 million
people. Most of the doses will be made in Japan by Daiichi
Sankyo, JCR Pharma  4552.T  and other local partners.
 urn:newsml:reuters.com:*:nL4N2F92XN

 (Reporting by Rocky Swift; Editing by Jacqueline Wong)
 ((ran.kim@thomsonreuters.com; +81-3-4520-1228;))